Amicus Therapeutics Company Profile (NASDAQ:FOLD)

Analyst Ratings

Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (?)
Ratings Breakdown: 2 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $12.88 (91.59% upside)

Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016Leerink SwannReiterated RatingOutperform$17.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016Bank of America Corp.Initiated CoverageBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016Robert W. BairdInitiated CoverageNeutral$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Chardan CapitalBoost Price TargetBuy$10.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman Sachs Group Inc.Initiated CoverageNeutral$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Janney Montgomery ScottUpgradeNeutral -> Buy$10.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016Cowen and CompanyReiterated RatingOutperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016JPMorgan Chase & Co.Reiterated RatingBuy$18.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2015B. RileyBoost Price TargetBuy$14.00 -> $17.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Amicus Therapeutics (NASDAQ:FOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2016Q4($0.31)($1.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.24)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.21)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015Q414($0.18)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014($0.21)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014($0.23)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2014($0.24)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2014Q4 13($0.32)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2013Q3($0.32)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Amicus Therapeutics (NASDAQ:FOLD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Amicus Therapeutics (NASDAQ:FOLD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Amicus Therapeutics (NASDAQ:FOLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/27/2016Jay BarthInsiderSell20,916$7.00$146,412.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Amicus Therapeutics (NASDAQ:FOLD)
DateHeadline
07/29/16 04:11 PMThe Insider Activity Don't Lie: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Review Fortune
07/29/16 03:14 PMAMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib -
07/29/16 11:08 AMStock's Ratings to Focus: Amicus Therapeutics, Inc. (NASDAQ:FOLD ... - Street Updates
07/27/16 04:17 PMAmicus Therapeutics, Inc. (NASDAQ:FOLD): Updated Analyst Ratings - Review Fortune
07/27/16 05:31 AMStocks Movements to Focus: Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) , Amicus Therapeutics, Inc. (NASDAQ ... - Street Updates
07/27/16 05:31 AMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Insiders Look Optimistic About Prospects - Review Fortune
07/27/16 05:31 AMAnalysts Reviewing Stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD) , Cara Therapeutics, Inc. (NASDAQ:CARA) - Street Updates
07/25/16 08:45 AMActive biotech company shares in the news: Amicus Therapeutics, Inc. (NASDAQ:FOLD), EPIRUS Biopharmaceuticals ... - The Voice Registrar
07/23/16 08:07 AMRedmile Group LLC Increased Amicus Therapeutics INC (NASDAQ:FOLD) by $3.50 Million as Shares Declined - Consumer Eagle
07/22/16 04:26 AM3 Stocks to Watch For: Amicus Therapeutics, Inc. (FOLD), Mast Therapeutics, Inc. (MSTX), Lions Gate Entertainment ... - iStreetWire
07/22/16 04:26 AMStocks inside Analysts Spotlight: Mylan N.V. (NASDAQ:MYL) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates
07/22/16 04:26 AMBiotech Stocks Worth a Closer Look: Amicus Therapeutics (NASDAQ:FOLD), Keryx Biopharmaceuticals (NASDAQ:KERX) - The Voice Registrar
07/21/16 07:35 AMAmicus Therapeutics, Inc. (NASDAQ:FOLD): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 07:35 AMNoticeable Analyst's ideas: Cerus Corporation (NASDAQ:CERS) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates
07/19/16 09:22 PMHow Analysts Rated Amicus Therapeutics, Inc. (NASDAQ:FOLD) Last Week? - Press Telegraph
07/18/16 09:13 AMAnalysts Review of Stocks: UnitedHealth Group Incorporated (NYSE:UNH) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates
07/18/16 09:13 AMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Wall Street Analyst Recommendation Outlook - TGP
07/18/16 09:13 AMAmicus Therapeutics, Inc. (FOLD) Broker Price Targets For The Coming Week - Fiscal Standard
07/18/16 09:13 AMEye Catching Stock for investors: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - News Oracle
07/16/16 07:31 AMShares Experiencing a Downtrend: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - TGP
07/15/16 03:07 PMStocks Under Consideration: Amicus Therapeutics, Inc. (FOLD), Hess Corporation (HES), Targa Resources Corp. (TRGP) - iStreetWire
07/15/16 04:40 AMTrading the Biotech News: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - The Voice Registrar
07/15/16 04:40 AMAmicus Therapeutics Incorporated (NASDAQ:FOLD) Short Interest Increased By 2.15% - Consumer Eagle
07/15/16 04:40 AMAmicus Therapeutics Inc Realized Volatility Hits Extreme Level - CML News
07/15/16 04:40 AMA Look At Amicus Therapeutics - Seeking Alpha
07/14/16 04:13 PMA Look At Amicus Therapeutics
07/14/16 07:23 AMNews review of 2 biotech stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Amgen Inc. (NASDAQ:AMGN) - The Voice Registrar
07/12/16 04:14 PMTrading the Biotech News: Amicus Therapeutics (FOLD), Merrimack Pharmaceuticals (NASDAQ:MACK) - The Voice Registrar
07/12/16 04:14 PMRecent Analysts Rating Overview: Community Health Systems, Inc. (NYSE:CYH) , Amicus Therapeutics, Inc. (NASDAQ ... - Street Updates
07/12/16 04:14 PMStocks Under Review: Amicus Therapeutics, Inc. (FOLD) Celldex Therapeutics, Inc. (CLDX) Keryx Biopharmaceuticals ... - iStreetWire
07/12/16 04:14 PMHot Stock under Consideration: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - News Oracle
07/12/16 06:30 AMAmicus Therapeutics Appoints Former FDA Division Deputy Director Andrew Mulberg as Vice President, Regulatory Strategy - [GlobeNewswire] - Former Deputy Director of FDA Division of Gastroenterology and Inborn Errors Products. Brings Significant Drug Development and Pharmaceutical Industry Experience. CRANBURY, N.J., July 12, 2016-- Amicus ...
07/11/16 08:50 AMCompany Shares of Amicus Therapeutics (NASDAQ:FOLD) Rally 4.53% - TheFounders Daily
07/07/16 09:17 PMHeightened Volatility Check on: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Engelwood Daily
07/07/16 09:17 PMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Starts New Pre-Clinical Program - Small Cap Exclusive (press release)
07/07/16 04:55 AMCan Amicus Therapeutics, Inc. (NASDAQ:FOLD) Improve on the Earnings Front? - Engelwood Daily
07/07/16 04:55 AMInsiders Increasing Positions in: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Press Telegraph
07/07/16 04:55 AMAmicus Therapeutics (FOLD) Commences Preclinical Program for CDKL5 Deficiency - StreetInsider.com
07/06/16 04:09 PMAmicus Therapeutics Expands Biologics Pipeline with New Preclinical Program for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency
07/06/16 04:09 PMAmicus Therapeutics (FOLD) Commences Preclinical Program for CDKL5 Deficiency
07/06/16 03:07 PMAMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or -
07/01/16 05:13 AMLongwood Capital Partners LLC Increased Amicus Therapeutics INC (NASDAQ:FOLD) by $7.98 Million as Shares ... - Press Telegraph
07/01/16 05:13 AMShort Term Price Target on Amicus Therapeutics (FOLD) - Trade Calls
07/01/16 05:05 AMAMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia -
06/30/16 05:13 AMAnalyst Rating Update on Amicus Therapeutics (FOLD) - TheFounders Daily
06/29/16 05:22 AMAmicus Therapeutics, Inc. on Focus After Raising In Today's Session - Press Telegraph
06/28/16 08:55 AMCovering the Bases on Amicus Therapeutics, Inc. (NASDAQ:FOLD): Where is the Stock Going? - Press Telegraph
06/27/16 03:58 PMToday's Hot List: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Barrick Gold Corporation (NYSE:ABX), Lennar ... - KC Register
06/27/16 08:30 AMAmicus Therapeutics Incorporated (NASDAQ:FOLD) Short Interest Increased By 2.15% - Engelwood Daily
06/27/16 08:30 AMNext Weeks Broker Price Targets For Amicus Therapeutics, Inc. (FOLD) - Fiscal Standard

Social

About Amicus Therapeutics

Amicus Therapeutics logoAmicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: FOLD
  • CUSIP: 03152W10
Key Metrics:
  • Previous Close: $6.72
  • 50 Day Moving Average: $5.92
  • 200 Day Moving Average: $6.84
  • P/E Ratio: N/A
  • P/E Growth: -0.10
  • Market Cap: $853.77M
  • Beta: 1.77
  • Current Year EPS Consensus Estimate: $-1.35 EPS
  • Next Year EPS Consensus Estimate: $-1.06 EPS
Additional Links:
Amicus Therapeutics (NASDAQ:FOLD) Chart for Saturday, July, 30, 2016